Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, Longmian Road, Nanjing 211198, China.
Atherosclerosis. 2012 Aug;223(2):350-8. doi: 10.1016/j.atherosclerosis.2012.06.012. Epub 2012 Jun 20.
We investigated whether diosgenin, a widely used steroidal sapogenin, exerted protection against palmitate (PA)-induced inflammation and insulin resistance in the endothelium.
Human umbilical vein endothelial cells (HUVECs) were pretreated with diosgenin for 30 min, and then incubated with 100 μmol/L PA for 30 min or 24 h with or without insulin. IKKβ, p65 phosphorylation, serine phosphorylation of insulin receptor substrate-1 (IRS-1) at S307, tyrosine phosphorylation of IRS-1, Akt and eNOS activation were determined by Western blot analysis. Levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6), endothelin-1 (ET-1) and plasminogen activator inhibitor-1 (PAI-1) were measured with ELISA Kits. Intracellular nitric oxide (NO) was viewed with fluorescence microscopy. Effects of diosgenin on insulin-mediated vasodilation was investigated in the isolated rat aortic rings.
Diosgenin significantly reduced PA-enhanced IKKβ and NF-κB phosphorylation with inhibition of TNF-α and IL-6 production in endothelial cells at the concentrations of 0.1, 1 and 10 μmol/L, well demonstrating its anti-inflammatory activity in an IKKβ/NF-κB-dependent fashion. Meanwhile, diosgenin attenuated PA-induced serine phosphorylation (S307) of IRS-1 and restored IRS-1 tyrosine phosphorylation in response to insulin. The beneficial modulation of serine/tyrosine phosphorylation of IRS-1 by diosgenin contributed to the improvement of insulin signaling along PI3K/Akt/eNOS pathways and thereby increased insulin-mediated NO production. Salicylate (5 mmol/L), an inhibitor of IKKβ, showed similar activities as diosgenin. Diosgenin also remarkably inhibited ET-1 and PAI-1 production in the endothelial cells, and markedly restored the loss of insulin-mediated vasodilation in the presence of PA.
The above-mentioned evidence suggests that diosgenin ameliorated endothelial dysfunction involved in insulin resistance through an IKKβ/IRS-1-dependent manner, shows potential application in the treatment for the cardiovascular diseases including atherosclerosis.
研究薯蓣皂苷元(一种广泛应用的甾体皂素)是否对棕榈酸(PA)诱导的内皮细胞炎症和胰岛素抵抗具有保护作用。
用薯蓣皂苷元预处理人脐静脉内皮细胞(HUVEC)30min,然后用 100μmol/LPA 孵育 30min 或 24h,同时或不同时加入胰岛素。用 Western blot 分析检测 IKKβ、p65 磷酸化、胰岛素受体底物-1(IRS-1)丝氨酸 307 位磷酸化、IRS-1 酪氨酸磷酸化、Akt 和 eNOS 激活。用 ELISA 试剂盒测定肿瘤坏死因子-α(TNF-α)和白细胞介素-6(IL-6)、内皮素-1(ET-1)和纤溶酶原激活物抑制剂-1(PAI-1)水平。用荧光显微镜观察细胞内一氧化氮(NO)。用离体大鼠主动脉环研究薯蓣皂苷元对胰岛素介导的血管舒张的影响。
薯蓣皂苷元在 0.1、1 和 10μmol/L 浓度下显著降低了 PA 增强的 IKKβ 和 NF-κB 磷酸化,抑制了内皮细胞中 TNF-α 和 IL-6 的产生,表明其具有 IKKβ/NF-κB 依赖性的抗炎活性。同时,薯蓣皂苷元减弱了 PA 诱导的 IRS-1 丝氨酸磷酸化(S307),并恢复了 IRS-1 对胰岛素的酪氨酸磷酸化。薯蓣皂苷元对 IRS-1 丝氨酸/酪氨酸磷酸化的有益调节有助于改善 IRS-1 沿 PI3K/Akt/eNOS 通路的胰岛素信号转导,从而增加胰岛素介导的 NO 产生。IKKβ 的抑制剂水杨酸(5mmol/L)表现出与薯蓣皂苷元相似的活性。薯蓣皂苷元还显著抑制内皮细胞中 ET-1 和 PAI-1 的产生,并显著恢复存在 PA 时胰岛素介导的血管舒张的丧失。
上述证据表明,薯蓣皂苷元通过 IKKβ/IRS-1 依赖性途径改善了与胰岛素抵抗相关的内皮功能障碍,在包括动脉粥样硬化在内的心血管疾病的治疗中具有潜在的应用价值。